A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with endometrial cancer that has come back, does not respond to treatment, or has spread to other places in the body. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome Measures:
1. Progression-free survival [ Time Frame: From the date of study enrollment to the investigator-determined date of progression, or death due to any cause, whichever occurs first, assessed up to 5 years ]
Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Will be tested using pairwise log-rank tests stratified by the factors.
Secondary Outcome Measures:
1. Overall survival [ Time Frame: From the date of study enrollment to the date of death regardless of the cause, assessed up to 5 years ]
Will be tested using pairwise log-rank tests stratified by the factors.
2. Objective tumor response [ Time Frame: Up to 5 years ]
Will be assessed by RECIST version 1.1. Will be tested using pairwise Cochran-Mantel-Haenszel tests stratified by the factors.
Can be done from home
KeywordsCediranib Maleate, Olaparib
Principal InvestigatorMerry Jennifer Markham, MD
Sponsoring GroupDepartment of Medicine
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.